IRD vs OCGN
IRD: Clinical-stage biopharmaceutical company developing AAV-based gene therapies to restore vision in patients with inherited retinal diseases. OCGN: A gene therapy company developing novel modifier gene therapies to treat inherited retinal diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy.
Side-by-side fundamentals
| Metric | IRD | OCGN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.05 | $1.29 | |
| Market cap as of 2026-07-23 | $252M | $440M | |
| PEG as of 2026-07-23 | n/a | -0.23 | |
| Net margin as of 2026-07-23 | -892.4% | -1158.6% | IRD higher |
| Gross margin as of 2026-07-23 | +87.5% | n/a | |
| Operating margin as of 2026-07-23 | -359.1% | -1057.5% | IRD higher |
| ROE as of 2026-07-23 | -316.4% | -1306.7% | IRD higher |
| ROA as of 2026-07-23 | -223.0% | -96.3% | OCGN higher |
| Debt / equity as of 2026-07-23 | 0.07 | 5.03 | IRD lower |
| Revenue growth (YoY) as of 2026-07-23 | -12.2% | +3.0% | OCGN higher |
| Revenue CAGR (3y) SEC XBRL | -29.1% | +21.0% | OCGN higher |
| Beta as of 2026-07-23 | 0.59 | 2.17 | |
| 1-year return as of 2026-07-22 close | +157.1% | +25.2% | IRD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.